Although the study was based on RNAi and overexpression approaches, our findings call for future investigation of EZH2 inhibitors in treating tumors, including prostate cancer, with low HNF1B expression mediated by EZH2 overexpression. The gene discussed is HNF1B; the disease is prostate carcinoma.